Tag: <span>Dacomitinib</span>

Home / Dacomitinib
Post

Dacomitinib in advanced lung cancer: Disadvantages outweigh survival advantage

by Institute for Quality and Efficiency in Health Care Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in an early benefit assessment whether...